Skip to main content

Table 1 Recent case reports in which antimyeloma drugs have been applied in HIV-negative PBL patients

From: A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report

Agent Author, year Combination Patients Setting Outcomes
Bortezomib Saba, 2013 [8] Single agent 1 Salvage PR; DOR 5 months; death
Yan, 2014 [9] Bor + Rituximab + Dex 1 Salvage nCR; 3+ months post-ASCT
Castillo, 2015 [10] Bor + DA-EPOCH 3 (*) First-line 3 CR; DOR 12+, 18+, 24+ months
Hirosawa, 2015 [11] Single agent 1 Salvage Transient regression
Fedele, 2016 [12] Bor + DA-EPOCH 1 First-line CR; DOR 24+ months
Cencini, 2016 [13] Bor + COMP 1 First-line CR; DOR 12 months
Lenalidomide Carras, 2015 [14] Single agent 1 Salvage CR; DOR 6 months
Schmit, 2017 [15] Len + cyclo + dex 1 First-line CR; DOR 24+ months
  1. (*) 2 HIV-positive patients included
  2. Bor bortezomib, Dex dexamethasone, DA-EPOCH dose-adjusted EPOCH, COMP same as CHOP, but with liposomal doxorubicin, Len lenalidomide, Cyclo cyclophosphamide. PR partial response, (n)CR (near) complete response, DOR duration of response, ASCT autologous transplantation. The sign “+” indicates an ongoing response at the moment of the report